Fig. 2.

BFA disrupts the ERGIC and Golgi in IBRS2 cells. IBRS2 cells were treated with DMSO (mock) or BFA (5 μg ml−1) for 0.5 h. (a, b) Mock-treated (a) and BFA-treated (b) cells labelled for ERGIC (ERGIC-53; green). (c, d) Mock-treated (c) and BFA-treated (d) cells labelled for Golgi (GM130; green). Nuclei are shown in blue. Bars, 10 μm.